Spotlight Growth
No Result
View All Result
Wednesday, July 6, 2022
  • Login
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

How to Play the COVID-19 Vaccine Race

by admin
March 5, 2021
in Bio/Med/Pharma, Opinion
0
How to Play the COVID-19 Vaccine Race

The world has shut down trying to avoid the coronavirus, or COVID-19. Individuals, companies and governments everywhere are getting hit hard where it hurts – in the wallet. Any company that can resolve the crisis in the form of prevention (a vaccine) or treatment stands to make windfall profits from immediate worldwide demand, not to mention an amazing boost for their brand and public relations. The following companies are in the race and here’s where they stand now.

Source: Google News
Source: Google News

Gilead Sciences

Gilead Sciences, Inc. (NASDAQ: GILD) was first out of the gate to announce a possible treatment for COVID-19. On February 26, they launched two clinical studies using their antiviral medication, Remdesivir. On April 10, they announced a successful trial with the drug, stating that people with severe coronavirus symptoms showed “clinical improvement.” The stock responded by shooting up $10.50, or 14% over six trading days.

It seems that many investors read the headline without diving into the details; the results are dubious at best. 36 of 53 people who received the drug (68%) saw improvement after using the drug for 10 days – but that’s meaningless. Most people recover from the virus anyway. Furthermore, the trial was rushed: experts say using such a small number of patients with highly varied symptoms, no control group, minimal follow-up, and missing data on several patients all make the data inconclusive. Also, seven people died within four weeks and 10 people showed no improvement. Still, Remdesivir has emerged as the frontrunner in a world desperate for a cure. If you’re very sick with the virus, a drug that might help is better than nothing.

Inovio Pharmaceuticals

Based in Pennsylvania, Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a small company by comparison.  They created a vaccine for COVID-19; now they need to find out if it works. (Who wants to be in the clinical trials for that? We’re going to infect you with the virus to see if our new vaccine works. What do you say? Take one for humanity.) On April 16, Inovio announced they received $6.9 million funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to conduct the clinical trials for the vaccine, named INO-4800, in South Korea.

As of April 21, 2020, Inovio is one of only a few companies that are currently undergoing human trials for a potential COVID-19 vaccine. The clinical trials are taking place at the University of Pennsylvania Hospital. Inovio is also backed by the Bill and Melinda Gates Foundation.

Moderna

Moderna, Inc. (NASDAQ: MRNA), another relatively small company, has created its own vaccine and they’re moving forward at full speed. The company gave the vaccine to their first patient on March 16. They hope to start a Phase-3 trial on the vaccine involving thousands of patients within six months. The company announced that the federal government has committed to give them $483 million to help develop the vaccine.

GlaxoSmithKline-Sanofi Partnership

Two big players, GlaxoSmithKline (NYSE: GSK) and Sanofi (NASDAQ: SNY), announced they will be working together and leveraging each company’s expertise to develop a vaccine. Sanofi will work to identify an antigen required to make a vaccine using Glaxo technology. They have an optimistic timeline: the vaccine could be available to hundreds of millions of people by the end of 2021. If the pieces all come together, they have the resources to make it happen.

Tracking The COVID-19 Cure

The Milken Institute is tracking progress toward the cure to COVID-19. They currently report that 86 vaccines are being developed, in addition to 45 treatments involving anti-bodies, 20 anti-viral drugs, 9 cell-based therapies, 5 RNA-based treatments, and 47 other treatments.

Source: Milken Institute
Source: Milken Institute

How To Invest

A lot of very smart people are working on this; someone is going to find the cure. And when they do, the rewards will be great. However, there is no way to know who will win the race. Even the scientists and researchers themselves can’t answer that. It’s even possible that the virus will die out on its own, removing the immediate need to develop a cure. Trying to determine which company to invest in to score on the COVID-19 cure is a crapshoot.

I prefer to make investments based on solid reasoning, not luck. I invest in companies with steadily increasing sales and profits and a bright outlook. Investing this way offers better odds of success. Investing in any of these companies this early on feels too much to me like buying a lottery ticket, or betting on red or black. I’m going to stay on the sidelines on this one. Maybe you should, too.

Disclosure: The author, Gregg Killpack, Matt Rego or Spotlight Growth do not have any position or relationship with any companies mentioned in this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.

Article By: Gregg Killpack

Tags: biopharmabiopharmaceuticalsbiotechclinical trialscommon stockCOVID-19COVID-19 vaccineemerging growthGileadGlaxosmithklinehuman trialsInovioinvestinginvestmentmedicalmicrocap stocksMilken InstituteModernaNASDAQnewsNYSEopinionpharmaceuticalspublic companysalesSanofiservicessmall cap companiessmall cap stockssmall capsSouth KoreaSpotlight GrowthSpotlight Growth Stocksstock marketstocksstocks to watchtechtradingtreatment
Plugin Install : Widget Tab Post needs JNews - View Counter to be installed
  • Trending
  • Comments
  • Latest
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

November 22, 2021
Alfi NASDAQ ALF Ridesharing Tablet Rollout Spotlight Growth

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Waitr NASDAQ WRTH 7 Eleven Delivery Spotlight Growth

Waitr Holdings (NASDAQ: WTRH) Expands Delivery Reach with New National Collaboration with 7-Eleven

July 6, 2022
Resolute Paper Products NYSE RFP Paper Excellence Group Takeover Spotlight Growth

Resolute Forest Products (NYSE: RFP) Enters into Agreement to be Acquired by Paper Excellence Group for $2.7 Billion

July 6, 2022
Inspira Technologies NASDAQ IINN Hyla Blood Sensor Spotlight Growth

Inspira Technologies (NASDAQ: IINN) Unveils Non-Invasive Blood Sensor that Provides Real-Time Changes in Patients

July 6, 2022
5 Micro-Cap Stocks That Are the Best Performers Through the First Half of 2022 Spotlight Growth

5 Best Performing Micro-Cap Stocks Through the First Half of 2022

July 5, 2022

Recent News

Waitr NASDAQ WRTH 7 Eleven Delivery Spotlight Growth

Waitr Holdings (NASDAQ: WTRH) Expands Delivery Reach with New National Collaboration with 7-Eleven

July 6, 2022
Resolute Paper Products NYSE RFP Paper Excellence Group Takeover Spotlight Growth

Resolute Forest Products (NYSE: RFP) Enters into Agreement to be Acquired by Paper Excellence Group for $2.7 Billion

July 6, 2022

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us
Spotlight Growth

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested